Evidence map›Paper›PMID 41556287›Full record

ArticleDrug delivery2026

The colloidal stability of albumin-based drug delivery systems has a profound effect on tumoricidal activity.

Guojun Xiong, Chengwei Jiang, Andreas G Schätzlein, Ijeoma F Uchegbu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Guojun XiongSchool of Pharmacy, University College London, London, UK.
Chengwei JiangSchool of Pharmacy, University College London, London, UK.
Andreas G SchätzleinSchool of Pharmacy, University College London, London, UK.
Ijeoma F UchegbuSchool of Pharmacy, University College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human serum albumin (HSA) has attracted significant attention in drug delivery since the approval of Abraxane in 2005. Abraxane is a nanoparticle albumin-bound paclitaxel (nab-PTX) formulation. Although HSA offers advantages such as prolonged circulation time (half-life ~19 days) and intrinsic hydrophobic pockets, the translation of other HSA-based nanomedicines remains limited. In fact, the significant differences between native and pharmaceutical HSA in protein structure and biological interactions could hinder their translational use in drug delivery. In this study, we demonstrate that pharmaceutical HSA (

Indexed as

Albumin-Bound PaclitaxelAntineoplastic Agents, PhytogenicPaclitaxelSerum AlbuminSerum Albumin, HumanAnimalsCell Line, TumorColloidsDrug CarriersDrug Delivery SystemsDrug LiberationDrug StabilityHumansHydrophobic and Hydrophilic InteractionsMiceNanoparticlesAlbumin-Bound PaclitaxelAntineoplastic Agents, PhytogenicColloidsDrug CarriersPaclitaxelPolyesterspoly(lactide)Serum AlbuminSerum Albumin, HumanAbraxanecolloidal stabilitydenatured albumindrug deliveryHSA-PLAprotein engineering

Identifiers

PMID41556287
PMCPMC12821350

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.